Adverse effects of semaglutide compared to liraglutide: an integrative literature review




Adverse effects; Weight loss; Liraglutide.


Introduction: The treatment for obesity has shown great evolution in recent years. Liraglutide and semaglutide are drugs that act on weight loss, contributing to avoid the metabolic consequences that overweight can cause. As with all drugs, both have side effects, which influence treatment adherence. Objective: To search the literature for adverse reactions of semaglutide compared to liraglutide when used for weight loss. Methodology: The Cochrane Library, PubMED, LILACS, and CAPES databases were searched using the following keywords: "GLP-1", "adverse effects", "safety", "weight loss", "liraglutide", and "obesity", selecting articles in English and Portuguese published in the last 5 years. Reviews, meta-analyses, monographs, dissertation theses, books, incomplete articles, and studies whose population sample consisted of diabetics or that evaded the theme were excluded. Results: A final sample of 12 articles was selected. The main side effects in users of GLP-1 analogues were concentrated in the gastrointestinal system, namely nausea, vomiting, dyspepsia, constipation, diarrhea, and abdominal pain. Other systems also showed side symptoms, although at a lower frequency, such as central nervous system, cardiovascular, renal, and hepatic, as well as psychiatric events. The vast majority of the studies were conducted in adult participants, with only 1 in a sample of children. Few cases were classified as severe, with most symptoms being mild or moderate. Final Considerations: The use of semaglutide seems to be linked to side effects, especially in the gastrointestinal tract, of greater intensity when compared to liraglutide. However, weight loss was shown to be greater in semaglutide users.


Albaker, W. et al. (2021). The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients. Int J Gen Med, 14, 8643-8650.

Blundell, J. et al. (2017). “Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.” Diabetes, obesity & metabolism, 19(9), 1242-1251.

Calderón, G. et al. (2022). Effectiveness of Anti-Obesity Medications Approved for Long-term Use in a Multidisciplinary Weight Management Program: A Multi-Center Clinical Experience. Int. J. Obes. (London), 46(3), 555-563.

Camkurt, M.A. et al. (2018). Liraglutide for psychiatric disorders: clinical evidence and challenges. Hormone Molecular Biology and Clinical Investigation, 36(2), 20180031.

Gao, L. et al. (2019). Neurological Manifestation of Incretin-Based Therapies in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Aging and Disease, 10(6), 1311-1319.

Guerrero-Hreins, E. et al. (2021). The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review. Prog Neuropsychopharmacol Biol Psychiatry, 110, 110303.

Ikushima, I. et al. (2018). A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Adv Ther., 35(4), 531-544.

Instituto Nacional de Diabetes e Doenças Digestivas e Renais. (2012). LiverTox: Informações clínicas e de pesquisa sobre lesão hepática induzida por drogas [Internet]. Bethesda (MD).

Knudsen, L.B. & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in endocrinology, 10, 155.

Kushner, R.F. et al. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring, Md.), 28(6), 1050-1061.

Larsen, J.R. et al. (2017). Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder. JAMA, 74(7), 719-728.

Lundgren, J. R. et al. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. The New England Journal of Medicine, 384, 1719-1739.

Mastrandrea, L.D et al. (2019). Liraglutide effects in a paediatric (7‐11 y) population with obesity: A randomized, double‐blind, placebo‐controlled, short‐term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatric Obesity, 14(5), e12495.

Medeiros, C.D. (2021). Uso da semaglutida como agente emagrecedor: uma revisão de literatura. Monografia apresentada ao Curso de Biomedicina do Centro Universitário Maria Milza, Governador Mangabeira – BA.

Müller, T.D. et al. (2019). Glucagon-like peptide 1 (GLP-1). Mol Metab., 30, 72-130.

Nauck, M.A et al. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular metabolism, 46, 101102.

O’Neil, P.M. et al. (2017). Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab.; 19, (11), 1529-1536.

Rakipovski, G. et al. (2018). The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways. JAAC Basic Transl Sci., 3(6), 844-857.

Rubino, D. et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1-12.

Rubino, D.M. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. JAMA, 327(2), 138-150.

Sharma, D. et al. (2018). Recent updates on GLP-1 agonists: Current advancements & challenges. Biomedicine & Pharmacotherapy, 108, 952-962.

Smits, M.M., Raalte, D.H.V. (2021). Safety of Semaglutide. Front. Endocrinol. (Lausanne), 12, 645563.

Souza, M. T. (2010). Integrative review: what is it? How to do it? Einstein.8(1)102-106.

Verma, S. et al. (2020). Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes, Obes Metab, 22(12), 2487-2492.

Trujillo, J.M.; Nuffer, W.; & Smith, B.A. (2021). GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv. Endocrinol. Metab., 12, 2042018821997320.

Wadden, T.A. et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA, 325(14), 1-11.

Wadden, T.A. et al. (2020). Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial. Obesity (Silver Spring), 28(3), 529-536.

Wilding, J.P.H et al. (2021). Once-weekly Semaglutide in Adults with overweight or obesity. The New England Journal of Medicina, 384, 989-1002.

Yanovski, S.Z. & Yanovski, J.A. (2021). Progress in Pharmacotherapy for Obesity. JAMA, 326(2), 129-130.



How to Cite

MORAES, A. L. S. M. de .; VILELA, B. S. .; SOUZA, B. C. .; FALLEIROS , I. de F. I. .; PEREIRA , I. L. .; RIBEIRO , J. S. O. . Adverse effects of semaglutide compared to liraglutide: an integrative literature review. Research, Society and Development, [S. l.], v. 11, n. 10, p. e579111033181, 2022. DOI: 10.33448/rsd-v11i10.33181. Disponível em: Acesso em: 2 dec. 2022.



Health Sciences